Idera Pharmaceuticals Operating Income 2006-2021 | IDRA

Idera Pharmaceuticals operating income from 2006 to 2021. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Idera Pharmaceuticals Annual Operating Income
(Millions of US $)
2020 $-37
2019 $-46
2018 $-61
2017 $-66
2016 $-39
2015 $-49
2014 $-39
2013 $-18
2012 $-20
2011 $-26
2010 $-18
2009 $7
2008 $1
2007 $-15
2006 $-17
2005 $-14
Idera Pharmaceuticals Quarterly Operating Income
(Millions of US $)
2021-06-30 $-8
2021-03-31 $-10
2020-12-31 $-8
2020-09-30 $-7
2020-06-30 $-8
2020-03-31 $-13
2019-12-31 $-12
2019-09-30 $-11
2019-06-30 $-12
2019-03-31 $-11
2018-12-31 $-12
2018-09-30 $-12
2018-06-30 $-16
2018-03-31 $-20
2017-12-31 $-15
2017-09-30 $-15
2017-06-30 $-22
2017-03-31 $-15
2016-12-31 $1
2016-09-30 $-13
2016-06-30 $-14
2016-03-31 $-13
2015-12-31 $-12
2015-09-30 $-11
2015-06-30 $-13
2015-03-31 $-13
2014-12-31 $-12
2014-09-30 $-10
2014-06-30 $-8
2014-03-31 $-9
2013-12-31 $-6
2013-09-30 $-5
2013-06-30 $-4
2013-03-31 $-4
2012-12-31 $-4
2012-09-30 $-5
2012-06-30 $-5
2012-03-31 $-5
2011-12-31 $-7
2011-09-30 $-6
2011-06-30 $-6
2011-03-31 $-7
2010-12-31 $-6
2010-09-30 $-5
2010-06-30 $-5
2010-03-31 $-2
2009-12-31 $4
2009-09-30 $0
2009-06-30 $4
2009-03-31 $-0
2008-12-31 $0
2008-09-30 $2
2008-06-30 $1
2008-03-31 $-2
2007-12-31 $-5
2007-09-30 $-4
2007-06-30 $-3
2007-03-31 $-3
2006-12-31 $-5
2006-09-30 $-4
2006-06-30 $-4
2006-03-31 $-4
2005-12-31 $-4
2005-09-30 $-3
2005-06-30 $-4
2005-03-31 $-3
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.058B $0.001B
Idera Pharmaceuticals, Inc. is a drug discovery and development company that is developing drug candidates to treat cancer and infectious, respiratory, and autoimmune diseases, and for use in combination with therapeutic and prophylactic vaccines. Idera's proprietary drug candidates are designed to modulate Toll-like Receptors, the body's first line of immune defense. Idera's pioneering DNA chemistry expertise enables it to identify drug candidates for internal development and creates opportunities for multiple collaborative alliances.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71